# Phase 5 Gate Report

- Phase: 5 - Project Development / Advancement
- Effective-spec SHA256: 855799897F8D519E9859EBC208DC1590017D2345464CED178E4E078B04CB5666
- Entry commit: b2e865f6a64807afbadc89bdec7b6edc659957fc
- Overall gate: PASS
- P0: 0
- P1: 0

## 1. Advancement object and timing

| Requirement | Result | Evidence |
|---|---|---|
| Canonical \(x_i\) meaning | PASS | original-drug innovation investment / project-advancement intensity |
| Clinical-development boundary | PASS | broader than pure clinical-development effort |
| Patent/research boundary | PASS | not patent applications, patent-generating effort, basic research or upstream discovery |
| Common control | PASS | one \(x_i\); no \(x_{ig}\), \(x_i^R\) or \(x_i^D\) |
| Timing | PASS | \(x_i\) is chosen before the project draw and route choice |
| Arrival technology | PASS | \(\lambda_i^{\mathrm{plan}}=a_ix_i\); \(a_i\) is predetermined advancement productivity |

## 2. Expected optimized value

\[
\Omega_i(M,p_m)
=
\int W_i(q,m;M,p_m)\,dF(q,m).
\]

- The expectation uses the deterministic Phase 4 maximum, not a logit
  inclusive value.
- Abandonment is available at value zero, so \(W_i\geq0\) and
  \(\Omega_i\geq0\).
- Measurability and integrability are stated explicitly.
- \(k_i\) affects \(\Omega_i\) through manufacturing organization and route
  value, not through project-arrival productivity or advancement cost.

Result: PASS.

## 3. FOC, SOC and global optimizer

The unified cost is
\[
C_X(x_i)=\frac{\kappa}{1+\nu}x_i^{1+\nu},
\qquad \kappa>0,\quad \nu>0.
\]
The objective is
\[
\max_{x_i\geq0}
\left\{
\beta a_ix_i\Omega_i-C_X(x_i)
\right\}.
\]

| Proof obligation | Result |
|---|---|
| KKT | PASS: nonnegative control, dual inequality and complementarity stated with correct signs |
| Interior FOC | PASS: \(\kappa x_i^\nu=\beta a_i\Omega_i\) |
| SOC | PASS: \(-\kappa\nu x_i^{\nu-1}<0\) for \(x_i>0\) |
| Global concavity | PASS: \(x_i^{1+\nu}\) strictly convex for every \(\nu>0\) |
| Existence | PASS: superlinear cost dominates the linear benefit |
| Uniqueness | PASS: strict concavity |
| Closed form | PASS: \(x_i^*=[\beta a_i\Omega_i/\kappa]^{1/\nu}\) |
| Zero-value corner | PASS: \(\Omega_i=0\Rightarrow x_i^*=0\) |
| Positive-value case | PASS: \(\Omega_i>0\) gives the unique interior solution |
| Quadratic boundary | PASS: \(\nu=1\) |

## 4. Dimensions

| Object | Units | Result |
|---|---|---|
| \(x_i\) | \(\mathsf X\) | PASS |
| \(a_i\) | \(\mathsf P/\mathsf X\) | PASS |
| \(\lambda_i^{\mathrm{plan}}\) | \(\mathsf P\) | PASS |
| \(\Omega_i\) | \(\mathsf C/\mathsf P\) | PASS |
| \(\kappa\) | \(\mathsf C/\mathsf X^{1+\nu}\) | PASS |
| \(C_X\) | \(\mathsf C\) per decision cohort | PASS |
| FOC sides | \(\mathsf C/\mathsf X\) | PASS |
| term inside optimal-intensity brackets | \(\mathsf X^\nu\) | PASS |

## 5. Fixed-price binary MAH channel

At fixed \(p_m\), Phase 4 gives a pointwise weak route-value gain. Therefore
\[
\Omega_i(1,p_m)-\Omega_i(0,p_m)\geq0.
\]
The optimal intensity is strictly order preserving in \(\Omega_i\), so
\[
\Omega_i(1,p_m)>\Omega_i(0,p_m)
\quad\Longleftrightarrow\quad
x_i^*(1,p_m)>x_i^*(0,p_m).
\]

The strict effect requires a positive-probability set on which the newly
feasible entrusted route improves the pre-reform maximum. If that condition
fails, both expected value and advancement have a zero reform effect. This is
a finite comparison in binary \(M\), not a derivative with respect to \(M\),
and it is not the equilibrium-price effect through \(p_m^*\).

Result: PASS.

## 6. Downstream value-gap foundation

The appendix accounting identity
\[
K_i-B_i=\Omega_i
\]
turns the interior FOC into
\[
C_X'(x_i)=\beta a_i(K_i-B_i).
\]
The notation is consistently \(C_X\), not the old \(C_R\). The auxiliaries
\(B_i,K_i\) are not recursive states, and no artificial Bellman equation,
financial constraint or scientific-productivity channel is added.

Result: PASS.

## 7. Automated and LaTeX audit

- Initial complete automated result after scope-check corrections:
  118 PASS / 0 FAIL.
- Final READY_FOR_APPROVAL audit, including gate-report traceability checks:
  120 PASS / 0 FAIL.
- MiKTeX two-pass compile: PASS.
- Fatal errors: 0.
- Undefined references: 0.
- Duplicate labels: 0.
- Overfull/underfull boxes: 0.
- UTF-8 replacement/control characters: 0.
- Manuscript diff against locked base: empty.
- Collaborator ZIP in rebuild worktree: absent.

## 8. Traceability

| IDs | Result | Phase 5 evidence |
|---|---|---|
| RL-01, RL-02, RL-03, RL-04, RL-05, RL-06 | PASS | no forbidden taxonomy, state expansion, entry, growth, household or welfare block |
| RL-07 | PASS | \(a_i\) is predetermined and MAH invariant |
| RL-08, RL-09, RL-10 | PASS | no direct demand, quality, realization-probability or CMO-price shift |
| RL-11 | PASS | Phase 4 retained-holder meaning is preserved |
| RL-12, RL-13, RL-14 | PASS | no logit/inclusive value, continuous implementation parameter or imported state |
| RL-15 | PASS | manuscript unchanged |
| RL-16, RL-17, RL-18, RL-19, RL-20 | PASS | no identification/welfare claim; formal FOC/SOC, registered notation and dimensions |
| RL-21, RL-22, RL-23, RL-24 | PASS | v1.2 advancement object; no patent, upstream-research or forced breakthrough response |
| RL-25 | PASS | no split controls, financial constraint or research-development allocation |
| RL-26, RL-27, RL-28 | PASS | no patent contradiction, novelty ranking or financial-constraints reframing |
| AMD11-F | PASS | Phase 5 terminology, unified \(C_X\) and optimization implemented |
| AMD11-G | PASS | Akcigit-style downstream value-gap interpretation implemented without new states |
| AMD12-01 | PASS | corrected \(x_i\) definition and negative boundaries applied |
| P05-D01 | PASS | advancement technology, expected value, objective, FOC/SOC, optimizer and value gap complete |
| P05-G01 | PASS | \(C_X\) consistent; v1.2 boundary; MAH affects \(x_i^*\) only through \(\Omega_i\) |
| QA-PROOF-01 | PASS | KKT and interior FOC re-derived |
| QA-PROOF-02 | PASS | local SOC plus global strict-concavity proof |
| QA-PROOF-03 | PASS | all objective, FOC and optimizer dimensions checked |
| QA-PROOF-04 | PASS | derivative and monotonicity signs checked |
| QA-PROOF-05 | PASS | control domain and fixed conditioning objects stated |
| QA-PROOF-06 | PASS | binary finite comparison separated from derivatives |
| QA-PROOF-07 | PASS | fixed \(p_m\) separated from equilibrium \(p_m^*\) |
| QA-PROOF-08 | PASS | \(\Omega_i=0\), positive-value and \(\nu=1\) boundaries checked |
| QA-PROOF-09 | NOT APPLICABLE | CMO fixed point remains deferred to Phase 6 |
| QA-PROOF-10 | PASS | compilation and label/reference audit |
| QA-ECON-01 | PASS | only direct policy wedge remains route \(E\)'s institutional barrier |
| QA-ECON-02 | PASS | advancement, planning, route choice and observed outcomes remain distinct |
| QA-ECON-03 | PASS | entrusted route meaning unchanged |
| QA-ECON-04 | PASS | price feedback remains endogenous and deferred |
| QA-ECON-05 | PASS | no extension mechanism contaminates the baseline |
| QA-ECON-06 | NOT APPLICABLE | no empirical identification claim |
| QA-ECON-07 | PASS | advancement terminology matches the v1.2 object |
| QA-ECON-08 | PASS | no new external empirical claim |

All IDs from RL-01 through RL-28 are explicitly covered above.

## 9. Next-phase boundary

Phase 6 may combine the approved project mass and deterministic entrusted-route
choices with an explicit CMO supply problem, aggregate demand and market
clearing. Phase 5 itself contains no supplier choice, aggregate demand,
clearing equation or equilibrium-price sign claim.

Gate conclusion: Phase 5 is ready for approval. Under EXEC-GOV-001, a
zero-P0 final audit authorizes APPROVED status, a separate commit/push and
continuation to Phase 6 without another routine prompt.
